Del Pharmaceuticals
This article was originally published in The Tan Sheet
Executive Summary
Asks FDA to clarify suggestions on Del's proposed clinical study to support the efficacy of Auro-Dri. FDA asked that the study be conducted in subjects with a history of swimmer's ear and that a no treatment control be used in the study ("The Tan Sheet" Dec. 13, 1993, p. 5). In the letter, Del questioned the necessity of testing individuals with a history of swimmer's ear since Auro- Dri is indicated to help dry water-clogged ears and not for the prevention of swimmer's ear
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning